Hemodiafiltration (HD-HF): one year follow-up of nine hours weekly.
Data are presented concerning our experience with hemodiafiltration (HD-HF) in uremic patients. Ten patients previously submitted to regular dialysis treatment, cuprophane membrane (RDT), for the last year twelve hours weekly, were treated for one year, nine hours weekly, HD-HF. Five of ten had suffered discomfort by RDT and five spontaneously chose HD-HF owing to its shorter treatment period. The follow-up of the two treatment schedules did not show any significant difference in absolute and percentage values of small molecules. Hematocrit, body weight and blood arterial pressure were not different following both treatment. Patients submitted to HD-HF complained of no discomfort including patients suffering of dialytic discomfort under RDT. HD-HF has proved as useful and more comfortable than RDT in long-term treatment of patients with chronic renal failure.
D000328:Adult; D001769:Blood; D001794:Blood Pressure; D001835:Body Weight; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D010710:Phosphates / Q000097:blood; D014462:Ultrafiltration / Q000379:methods*
D010710:Phosphates